Risk factor
Very high price volatility
Weak & very vulnerable to price shocks
Poor trading liquidity
Profitability factor
Greatly overvalued vs peers
Very low or no dividends
Very poor margins and returns
Risk / Profitability
Risk: High
Profitability: Poor
About
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2...
Risk factor
Very high price volatility
Weak & very vulnerable to price shocks
Poor trading liquidity
Profitability factor
Greatly overvalued vs peers
Very low or no dividends
Very poor margins and returns
$ 1.28
About
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2...
